SAN DIEGO, May 31, 2017 /PRNewswire/ -- MyDx, Inc. (OTCQB: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for the Cannabis professional and retail consumer to correlate the chemical profile of cannabis with its therapeutic effect, today announces that the first batch from its 1,000 units of MyDx 2.0 were successfully assembled and passed a rigorous QA/QC screening process in its Silicon Valley manufacturing facility.
MyDx 2.0 Units Assembled and Successfully Passed QA/QC Screening
With a host of new features and upgrades, MyDx 2.0 is comprised of over 200 individual components, backed by over 50 patents, that are meticulously pieced together with the highest standards of quality in mind. The new units will fulfill orders on backlog and resupply inventory reserves.
"We have streamlined our QC software to expedite our QC testing procedures and improve overall quality control of our units coming to customers. This along with our updated software and hardware will help us further instill confidence in our technology with the crowd," stated Robert Vigil, VP of Software Engineering.
MyDx Intends to Strategically Invest in Marketing Campaigns that Maximize Exposure
To support the sales of its new product, MyDx intends to implement a new marketing campaign to maximize brand exposure and communicate MyDx's value proposition to the masses. The company is currently working with its consultants on how best to deploy its strategy.
Data, Software and Algorithm Upgrades with Greater CBD Specificity
"The MyDx One iOS 4.0 App significantly improves the speed and performance of its predecessor and allows for further improvements behind the scenes without the need for customers to download an App update," continued Mr. Vigil. The MyDx software team is also in the middle of the development of its next generation MyDx software, which will debut on the Android Platform, which has started to outpace new iOS registered and guest users. MyDx has also advanced its data accumulation and analytics capabilities by increasing the size and quality of its database and enhancing related software and analytics algorithms. The net result is improved overall device and mobile app performance as well as greater accuracy of CBD value detection among high CBD strains.
MyDx 2.0 Comes Equipped with the Latest Hardware and Firmware Developments from its Innovative R&D Department
New MyDx 2.0 handheld devices come with new hardware and firmware upgrades to allow for new sensors to be interchanged seamlessly with the CannaDx Sensor. Existing customers under the MyDx Care plan can send their units into MyDx to be upgraded free of charge. The MyDx R&D team has further confirmed the successful interchangeability of the upcoming AeroDx sensor in the MyDx 2.0 devices as well as the functionality of that sensor in measuring key parameters of air quality.
To learn more about the MyDx Analyzer, please see the HBO's Daily Vice News short video documentary.
To Learn More about Cannabis Testing, MyDx Technology, and the Science of Cannabis 2.0, please download the MyDx White Paper.
To view more images from our assembly line, please visit our MyDx Facebook Page.
About MyDx, Inc.
MyDx, Inc. (OTCQB: MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user's hand. The multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology. The MyDx AquaDx®, OrganaDx(™) and CannaDx(™) sensors are now commercialized, and the AeroDx® application is next in line. All sensors will be compatible with a MyDx App that empowers consumers to live a healthier life by revealing the chemical composition of what they eat, drink and inhale. For more information, please visit www.cdxlife.com.
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.
MyDx Shareholder Communications
800.814.4550 ext. 4
SOURCE MyDx, Inc.